Amgen Infergen may be marketed as hepatitis C relapse treatment, firm tells analysts.
Executive Summary
AMGEN INFERGEN MARKETING MAY TARGET HEPATITIS C RELAPSERS, statements by Chief Financial Officer Robert Attiyeh at a June 4 Paine Webber analysts meeting in New York City indicated. Attiyeh said that pivotal trials with the drug yielded a "durable response in 58% of the relapsers" who have undergone existing interferon therapy. Infergen (consensus interferon) was deemed "approvable" by FDA in April. "We're simply negotiating the final terms and conditions of the package insert. We expect approval to go to the market later this year," Attiyeh said. Yamanouchi licensed rights to market Infergen in all markets except North America.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth